CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional...
Julia Han Noll, Devin Dersh, Jiang-Yuan Li et al.· Blood· 0 citations
Findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.
R. Shraim, Gong-Ping Shi, Yi-Zhen Li et al.· Blood· 0 citations
Collectively, epitope engineering of hematopoietic stem cells represents a versatile platform to expand the therapeutic window of precision immunotherapies and may enable safer, more effective combinatorial treatment strategies for both nonmalignant and malignant hematologic conditions.
Joanne Baek, G. Casirati, Pietro Genovese et al.· Blood Advances· 0 citations
A review of the biological rationale, delivery engineering, immunological barriers, CAR payload design, early clinical evidence, and future directions of this field focuses on the pharmacological principles that distinguish in vivo from ex vivo approaches and on the transformative potential for indications that lie bey...
Saar I Gill· Advances in Pharmacology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
